ELUVIA™

Drug-Eluting Vascular Stent System

The Eluvia Drug-Eluting Stent System demonstrated an unprecedented 96.1% primary patency at 12 months, the highest reported in comparable SFA clinical trials.

Key Resources

Resource Download Center Eluvia Stent Ordering Information
Anchor component is added but not authored

Product Details

product details for Eluvia Drug Eluting Vascular Stent System product details for Eluvia Drug Eluting Vascular Stent System

  

An innovative treatment option for the SFA that pushes patency beyond bare metal and drug-coated stents. The difference is a polymer-based drug-delivery technology that sustains dosing beyond one year.

Ordering Information

Eluvia Size Chart Eluvia Size Chart

Description UPN
Eluvia 6mm x 40mm x 75cm H74939295600470
Eluvia 6mm x 60mm x 75cm H74939295600670
Eluvia 6mm x 80mm x 75cm H74939295600870
Eluvia 6mm x 100mm x 75cm H74939295601070
Eluvia 6mm x 120mm x 75cm H74939295601270
Eluvia 6mm x 150mm x 75cm H74939295601570
Eluvia 7mm x 40mm x 75cm H74939295700470
Eluvia 7mm x 60mm x 75cm H74939295700670
Eluvia 7mm x 80mm x 75cm H74939295700870
Eluvia 7mm x 100mm x 75cm H74939295701070
Eluvia 7mm x 120mm x 75cm H74939295701270
Eluvia 7mm x 150mm x 75cm H74939295701570
Eluvia 6mm x 40mm x 130cm H74939295600410
Eluvia 6mm x 60mm x 130cm H74939295600610
Eluvia 6mm x 80mm x 130cm H74939295600810
Eluvia 6mm x 100mm x 130cm H74939295601010
Eluvia 6mm x 120mm x 130cm H74939295601210
Eluvia 6mm x 150mm x 130cm H74939295601510
Eluvia 7mm x 40mm x 130cm H74939295700410
Eluvia 7mm x 60mm x 130cm H74939295700610
Eluvia 7mm x 80mm x 130cm H74939295700810
Eluvia 7mm x 100mm x 130cm H74939295701010
Eluvia 7mm x 120mm x 130cm H74939295701210
Eluvia 7mm x 150mm x 130cm H74939295701510

See UPN Product Codes

Clinical Information

MAJESTIC Clinical Trial

Trial Overview

  • Core lab adjudicated single-arm, multicenter trial (n=57)
  • 65% of lesions severely calcified
  • 46% total occlusions
  • 71 mm average lesion length

96.1% Primary Patency, TLR 3.8%, 0 Stent Fractures at 12 months 96.1% Primary Patency, TLR 3.8%, 0 Stent Fractures at 12 months
MAJESTIC 12 month Kaplan-Meier Estimate: 96.4% MAJESTIC 12 month Kaplan-Meier Estimate: 96.4%

1Primary patency defined as duplex ultrasound peak systolic velocity ratio ≤2.5 and absence of TLR or bypass. Data on file at Boston Scientific.

Majestic Trial 12-month Results Rutherford Category for ELUVIA SFA drug-eluting stents (DES). Majestic Trial 12-month Results Rutherford Category for ELUVIA SFA drug-eluting stents (DES).

  • 94% of patients presented with no or minimal claudication at 12 months
  • ABI improvement sustained through 12 months

  

Related Technologies

Top